$0.30
39.37%
Nasdaq, Nov 22, 03:30 pm CET
ISIN
US81577F1093
Symbol
SEEL
Sector
Industry

Seelos Therapeutics, Inc. Stock price

$0.31
-0.91 74.58% 1M
-20.97 98.54% 6M
-177.61 99.83% YTD
-407.88 99.92% 1Y
-7,218.89 100.00% 3Y
-3,224.91 99.99% 5Y
-1,509,119.69 100.00% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.01 3.33%
ISIN
US81577F1093
Symbol
SEEL
Sector
Industry

Key metrics

Market capitalization $350.00k
Enterprise Value $10.22m
P/E (TTM) P/E ratio 0.00
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 5.08
P/S ratio (TTM) P/S ratio 0.17
P/B ratio (TTM) P/B ratio 0.00
Revenue growth (TTM) Revenue growth 76.05%
Revenue (TTM) Revenue $2.01m
EBIT (operating result TTM) EBIT $-29.81m
Free Cash Flow (TTM) Free Cash Flow $-13.27m
Cash position $290.00k
EPS (TTM) EPS $176.64
P/E forward negative
Short interest 29.52%
Show more

Is Seelos Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Seelos Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Seelos Therapeutics, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Seelos Therapeutics, Inc.:

Buy
100%

Financial data from Seelos Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
2.01 2.01
76% 76%
100%
- Direct Costs 0.06 0.06
25% 25%
3%
1.96 1.96
85% 85%
98%
- Selling and Administrative Expenses 11 11
7% 7%
561%
- Research and Development Expense 20 20
54% 54%
1,016%
-30 -30
46% 46%
-1,480%
- Depreciation and Amortization 0.06 0.06
25% 25%
3%
EBIT (Operating Income) EBIT -30 -30
46% 46%
-1,483%
Net Profit 4.09 4.09
105% 105%
203%

In millions USD.

Don't miss a Thing! We will send you all news about Seelos Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Seelos Therapeutics, Inc. Stock News

Neutral
PRNewsWire
about one month ago
NEW YORK , Oct. 24, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (OTCQB: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that its 2024 Annual Meeting of Stockholders (the "Annual Meeting"), which was previously postponed to Friday, October 25, 2024, from its originally ...
Neutral
PRNewsWire
about one month ago
NEW YORK , Oct. 15, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that on October 14, 2024, Seelos Therapeutics, Inc. (the "Company") received notice that the Nasdaq Hearings Panel (the "Panel") ha...
Neutral
PRNewsWire
2 months ago
NEW YORK , Sept. 26, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that its 2024 Annual Meeting of Stockholders (the "Annual Meeting"), which was originally scheduled to be held on September 27, 2024, has been post...
More Seelos Therapeutics, Inc. News

Company Profile

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system disorders. Its portfolio includes late-stage clinical assets targeting psychiatric and movement disorders. The company is headquartered in New York, NY.

Head office United States
CEO Raj Mehra
Employees 16
Founded 1987
Website www.seelostherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today